Jun Deng PhD

Executive Director @ J.P. Morgan

About

Please contact me directly at jun.deng@jpmorgan.com instead of sending a LinkedIn invitation. I led national business development at J.P. Morgan Startup Banking for Life sciences and Healthcare sectors. If you are a founder seeking banking support, please connect with me directly via email. We would love to learn about your business and explore collaboration opportunities. Jun Deng is an Executive Director on the J.P. Morgan Life Sciences Startup Banking team. She brings over a decade of experience as a venture capitalist in Silicon Valley, working closely with founders from the earliest stages of company formation through scaling, board governance, and successful exits. Jun holds a PhD in biomedical sciences and possesses deep expertise in biotech, healthcare, and emerging technologies, offering a unique blend of scientific insight and financial acumen.

Country

City

United States

Industry

Banking

Skill

Startups, Commercial Banking, Venture Capital, Healthcare, Fund Management, Cell Biology, Genetics, Biotechnology, Lifesciences, Investment, Investments, Operations Management, Organizational Leadership, Start-ups, Research

Experience

Executive Director

J.P. Morgan

2025-7 - Present · 1 yr 3 mos

San Francisco Bay Area

Managing Director

Ataraxia Partners

2024-8 - 2025-7 · 1 yr

San Francisco Bay Area

Investment Partner

Joyance Partners

2018 - 2025-7 · 7 yrs

SF-Bay Area

Investing in companies that, through science and tech, cultivate joy to improve the way we live.

Investment Partner

Social Starts

2018 - 2025-7 · 7 yrs

Tracks the social mobile technology is going to have its next big impact Named as the top VCs under 100M by Pitchbook

Investor

HealthTech Capital

2018 - 2025-7 · 7 yrs

Palo Alto

Created a strategic partnership between Joyance and HealthTech Capital, optimizing investment opportunities Funded and mentored startups that decrease healthcare costs or empower the patients by leveraging data insights

Investor

Osmosis.org from Elsevier

2018 - 2025-7 · 7 yrs

Acquired by Reed Elsevier (NYSE: RELX) https://technical.ly/2021/12/03/osmosis-acquired-elsivier/

Investor

Loop Genomics

2016-1 - 2025-7 · 9 yrs 7 mos

San Jose, California, United States

Acquired by Element Biosciences

Investor

JOYA

2024-3 - 2025-6 · 1 yr 4 mos

Los Angeles, California, United States

The First & Only Employee Benefit Dedicated to Preventative Skin Health & Wellness.

Board Observer

C the Signs

2023-1 - 2025-6 · 2 yrs 6 mos

London, England, United Kingdom

Investor

Volumetric

2019-10 - 2025-6 · 5 yrs 9 mos

Acquired by 3D System (NYSE:DDD) https://www.businesswire.com/news/home/20211027006115/en/Volumetric-to-Be-Acquired-by-3D-Systems-to-Advance-Tissue-and-Organ-Manufacturing